Next Article in Journal
Chiral Aspects of Local Anesthetics
Next Article in Special Issue
Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System
Previous Article in Journal
Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry
Previous Article in Special Issue
Cell Death Effects Induced by Sulforaphane and Allyl Isothiocyanate on P-Glycoprotein Positive and Negative Variants in L1210 Cells
Article

Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo

1
Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 5200, Thailand
2
Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai 5200, Thailand
3
Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
4
Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
5
Drug Delivery System Excellence Center, Prince of Songkla University, Hat-Yai, Songkhla 90110, Thailand
*
Author to whom correspondence should be addressed.
Academic Editors: Olga Pecháňová and Martina Cebova
Molecules 2020, 25(12), 2737; https://doi.org/10.3390/molecules25122737
Received: 25 May 2020 / Revised: 8 June 2020 / Accepted: 10 June 2020 / Published: 12 June 2020
(This article belongs to the Special Issue Biological Activity of Natural Substances and Their Derivatives)
Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. View Full-Text
Keywords: curcumin analogs; dehydrozingerone; prostate cancer; pharmacokinetic; anticancer curcumin analogs; dehydrozingerone; prostate cancer; pharmacokinetic; anticancer
Show Figures

Graphical abstract

MDPI and ACS Style

Mapoung, S.; Suzuki, S.; Fuji, S.; Naiki-Ito, A.; Kato, H.; Yodkeeree, S.; Sakorn, N.; Ovatlarnporn, C.; Takahashi, S.; Limtrakul, P. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo. Molecules 2020, 25, 2737. https://doi.org/10.3390/molecules25122737

AMA Style

Mapoung S, Suzuki S, Fuji S, Naiki-Ito A, Kato H, Yodkeeree S, Sakorn N, Ovatlarnporn C, Takahashi S, Limtrakul P. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo. Molecules. 2020; 25(12):2737. https://doi.org/10.3390/molecules25122737

Chicago/Turabian Style

Mapoung, Sariya, Shugo Suzuki, Satoshi Fuji, Aya Naiki-Ito, Hiroyuki Kato, Supachai Yodkeeree, Natee Sakorn, Chitchamai Ovatlarnporn, Satoru Takahashi, and Pornngarm Limtrakul. 2020. "Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo" Molecules 25, no. 12: 2737. https://doi.org/10.3390/molecules25122737

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop